[ 1 ] D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91(9):4082–5 link1

[ 2 ] Wnendt S, Finkam M, Winter W, Ossig J, Raabe G, Zwingenberger K. Enantioselective inhibition of TNF-α release by thalidomide and thalidomide-analogues. Chirality 1996;8(5):390–6 link1

[ 3 ] Bauer JF, Saleki-Gerhardt A, Narayanan BA, Chemburkar SR, Patel KM, Spiwek HO, et al., inventors; Abbott Laboratories, assignee. Polymorph of a pharmaceutical. United States patent US 8193367 B2. 2012 Jun 5.

[ 4 ] Bauer J, Spanton S, Henry R, Quick J, Dziki W, Porter W, et al.Ritonavir: An extraordinary example of conformational polymorphism. Pharm Res 2001;18(6):859–66 link1

[ 5 ] Huang LF, Tong WQ. Impact of solid state properties on developability assessment of drug candidates. Adv Drug Deliv Rev 2004;56(3):321–34 link1

[ 6 ] Lee AY, Erdemir D, Myerson AS. Crystal polymorphism in chemical process development. Annu Rev Chem Biomol Eng 2011;2:259–80 link1

[ 7 ] Sood J, Sapra B, Bhandari S, Jindal M, Tiwary AK. Understanding pharmaceutical polymorphic transformations I: Influence of process variables and storage conditions. Ther Deliv 2014;5(10):1123–42 link1

[ 8 ] Wu JX, Xia D, van den Berg F, Amigo JM, Rades T, Yang M, et al.A novel image analysis methodology for online monitoring of nucleation and crystal growth during solid state phase transformations. Int J Pharm 2012;433(1–2):60–70 link1

[ 9 ] Wallace AF, Hedges LO, Fernandez-Martinez A, Raiteri P, Gale JD, Waychunas GA, et al.Microscopic evidence for liquid-liquid separation in supersaturated CaCO3 solutions. Science 2013;341(6148):885–9 link1

[10] Kuhs M, Zeglinski J, Rasmuson ÅC. Influence of history of solution in crystal nucleation of fenoxycarb: Kinetics and mechanisms. Cryst Growth Des 2014;14(3):905–15 link1

[11] Ito F, Suzuki Y, Fujimori J, Sagawa T, Hara M, Seki T, et al.Direct visualization of the two-step nucleation model by fluorescence color changes during evaporative crystallization from solution. Sci Rep 2016;6:22918 link1

[12] Srisanga S, Flood AE, Galbraith SC, Rugmai S, Soontaranon S, Ulrich J. Crystal growth rate dispersion versus size-dependent crystal growth: Appropriate modeling for crystallization processes. Cryst Growth Des 2015;15(5):2330–6 link1

[13] Mascia S, Heider PL, Zhang H, Lakerveld R, Benyahia B, Barton PI, et al.End-to-end continuous manufacturing of pharmaceuticals: Integrated synthesis, purification, and final dosage formation. Angew Chem Int Ed 2013;52(47):12359–63 link1

[14] Myerson AS, Krumme M, Nasr M, Thomas H, Braatz RD. Control systems engineering in continuous pharmaceutical manufacturing. May 20–21, 2014 Continuous Manufacturing Symposium. J Pharm Sci 2015;104(3):832–9 link1

[15] Adamo A, Beingessner RL, Behnam M, Chen J, Jamison TF, Jensen KF, et al.On-demand continuous-flow production of pharmaceuticals in a compact, reconfigurable system. Science 2016;352(6281):61–7 link1

[16] Woo XY, Tan RB, Braatz RD. Precise tailoring of the crystal size distribution by controlled growth and continuous seeding from impinging jet crystallizers. CrystEngComm 2011;13(6):2006–14 link1

[17] Kee NC, Tan RB, Braatz RD. Selective crystallization of the metastable α-form of L-glutamic acid using concentration feedback control. Cryst Growth Des 2009;9(7):3044–51 link1

[18] Singh MR. Towards the control of crystal shape and morphology distributions in crystallizers [dissertation]. West Lafayette: Purde University; 2013.

[19] Wang Y, Chen A. Crystallization-based separation of enantiomers. In: Andrushko V, Andrushko N, editors Stereoselective synthesis of drugs and natural products, two volume set. 1st ed. Hoboken: John Wiley & Sons, Inc.; 2013. p. 1663–82 link1

[20] Nagy ZK, Fevotte G, Kramer H, Simon LL. Recent advances in the monitoring, modelling and control of crystallization systems. Chem Eng Res Des 2013;91(10):1903–22 link1

[21] US Food and Drug Administration. Pharmaceutical cGMPs for the 21st century—A risk based approach. Final report. US Food and Drug Administration; 2004 Sep.

[22] Chew W, Sharratt P. Trends in process analytical technology. Anal Methods 2010;2(10):1412–38 link1

[23] Nagy ZK, Braatz RD. Advances and new directions in crystallization control. Annu Rev Chem Biomol Eng 2012;3:55–75 link1

[24] Yang Y, Nagy ZK. Advanced control approaches for combined cooling/antisolvent crystallization in continuous mixed suspension mixed product removal cascade crystallizers. Chem Eng Sci 2015;127:362–73 link1

[25] Yang Y, Song L, Nagy ZK. Automated direct nucleation control in continuous mixed suspension mixed product removal cooling crystallization. Cryst Growth Des 2015;15(12):5839–48 link1

[26] Raphael M, Rohani S. Sunflower protein precipitation in a tubular precipitator. Can J Chem Eng 1999;77(3):540–54 link1

[27] Alvarez AJ, Myerson AS. Continuous plug flow crystallization of pharmaceutical compounds. Cryst Growth Des 2010;10(5):2219–28 link1

[28] Brown CJ, Ni XW. Evaluation of growth kinetics of antisolvent crystallization of paracetamol in an oscillatory baffled crystallizer utilizing video imaging. Cryst Growth Des 2011;11(9):3994–4000 link1

[29] McGlone T, Briggs NE, Clark CA, Brown CJ, Sefcik J, Florence AJ. Oscillatory flow reactors (OFRs) for continuous manufacturing and crystallization. Org Process Res Dev 2015;19(9):1186–202 link1

[30] Jiang X, Lu D, Wu X, Ruan X, Fang J, He G. Membrane assisted cooling crystallization: Process model, nucleation, metastable zone, and crystal size distribution. AIChE J 2016;62(3):829–41 link1

[31] Lakerveld R, van Krochten JJ, Kramer HJ. An air-lift crystallizer can suppress secondary nucleation at a higher supersaturation compared to a stirred crystallizer. Cryst Growth Des 2014;14(7):3264–75 link1

[32] Liu WJ, Ma CY, Wang XZ. Novel impinging jet and continuous crystallizer design for rapid reactive crystallization of pharmaceuticals. Procedia Eng 2015;102:499–507 link1

[33] Yazdanpanah N, Ferguson ST, Myerson AS, Trout BL. Novel technique for filtration avoidance in continuous crystallization. Cryst Growth Des 2016;16(1):285–96 link1

[34] Schmidt GM. Photodimerization in the solid state. Pure Appl Chem 1971;27(4):647–78 link1

[35] Mahata G, Dey S, Chanda J. Crystal engineering: A powerful tool towards designing pharmaceutical solids with desirable physicochemical properties. Am J Drug Dis 2014;1(1):1–9.

[36] Cherukuvada S, Nangia A. Eutectics as improved pharmaceutical materials: Design, properties and characterization. Chem Commun 2014;50(8):906–23 link1

[37] Desiraju GR. Crystal engineering: A holistic view. Angew Chem Int Ed 2007;46(44):8342–56 link1

[38] LlinàsA, Goodman JM. Polymorph control: Past, present and future. Drug Discov Today 2008;13(5–6):198–210 link1

[39] Mirmehrabi M, Rohani S. An approach to solvent screening for crystallization of polymorphic pharmaceuticals and fine chemicals. J Pharm Sci 2005;94(7):1560–76 link1

[40] Allesø M, van den Berg F, Cornett C, Jørgensen FS, Halling-Sørensen B, de Diego HL, et al.Solvent diversity in polymorph screening. J Pharm Sci 2008;97(6):2145–59 link1

[41] Pfund LY, Matzger AJ. Towards exhaustive and automated high-throughput screening for crystalline polymorphs. ACS Comb Sci 2014;16(7):309–13 link1

[42] Storey R, Docherty R, Higginson P, Dallman C, Gilmore C, Barr G, et al.Automation of solid form screening procedures in the pharmaceutical industry—How to avoid the bottlenecks. Crystallogr Rev 2004;10(1):45–56 link1

[43] Kralj D, Brečević L, Kontrec J. Vaterite growth and dissolution in aqueous solution III. Kinetics of transformation. J Cryst Growth 1997;177(3–4):248–57 link1

[44] Sheikholeslamzadeh E, Rohani S. Modeling and optimal control of solution mediated polymorphic transformation of L-glutamic acid. Ind Eng Chem Res 2013;52(7):2633–41 link1

[45] Trifkovic M, Rohani S, Sheikhzadeh M. Kinetics estimation and polymorphic transformation modeling of buspirone hydrochloride. J Cryst Process Technol 2012;2(2):31–43 link1

[46] Simone E, Saleemi AN, Nagy ZK. In situ monitoring of polymorphic transformations using a composite sensor array of Raman, NIR, and ATR-UV/vis spectroscopy, FBRM, and PVM for an intelligent decision support system. Org Process Res Dev 2015;19(1):167–77 link1

[47] Takeguchi K, Obitsu K, Hirasawa S, Orii R, Ieda S, Okada M, et al.Effect of temperature and solvent of solvent-mediated polymorph transformation on ASP3026 polymorphs and scale-up. Org Process Res Dev 2016;20(5):970–6 link1

[48] US Food and Drug Administration. Guidance for industry: ANDAs: Pharmaceutical solid polymorphism: Chemistry, manufacturing, and controls information. Silver Spring: Center for Drug Evaluation and Research, US Food and Drug Administration; 2007 Jul.

[49] Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: Basic approaches and practical applications. Int J Pharm 2011;420(1):1–10 link1

[50] Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm 2004;58(2):265–78 link1

[51] Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12(3):413–20 link1

[52] Lin SY. Molecular perspectives on solid-state phase transformation and chemical reactivity of drugs: Metoclopramide as an example. Drug Discov Today 2015;20(2):209–22 link1

[53] Almeida e Sousa L, Reutzel-Edens SM, Stephenson GA, Taylor LS. Assessment of the amorphous “solubility” of a group of diverse drugs using new experimental and theoretical approaches. Mol Pharm 2015;12(2):484–95 link1

[54] Skrdla PJ, Floyd PD, Dell’orco PC. Practical estimation of amorphous solubility enhancement using thermoanalytical data: Determination of the amorphous/crystalline solubility ratio for pure indomethacin and felodipine. J Pharm Sci 2016;105(9):2625–30 link1

[55] Yu L. Amorphous pharmaceutical solids: Preparation, characterization and stabilization. Adv Drug Deliv Rev 2001;48(1):27–42 link1

[56] Dengale SJ, Grohganz H, Rades T, Löbmann K. Recent advances in co-amorphous drug formulations. Adv Drug Deliv Rev 2016;100:116–25 link1

[57] Löbmann K, Grohganz H, Laitinen R, Strachan C, Rades T. Amino acids as co-amorphous stabilizers for poorly water soluble drugs—Part 1: Preparation, stability and dissolution enhancement. Eur J Pharm Biopharm 2013;85(3 Pt B):873–81 link1

[58] US Food and Drug Administration. Naming of drug products containing salt drug substances; guidance for industry; availability. Silver Spring: Center for Drug Evaluation and Research, US Food and Drug Administration; 2015 Jun.

[59] Fernández Casares A, Nap WM, Ten Figás G, Huizenga P, Groot R, Hoffmann M. An evaluation of salt screening methodologies. J Pharm Pharmacol 2015;67(6):812–22 link1

[60] Serajuddin AT. Salt formation to improve drug solubility. Adv Drug Deliv Rev 2007;59(7):603–16 link1

[61] Saal C, Becker A. Pharmaceutical salts: A summary on doses of salt formers from the Orange Book. Eur J Pharm Sci 2013;49(4):614–23 link1

[62] Prohotsky DL, Zhao F. A survey of top 200 drugs—Inconsistent practice of drug strength expression for drugs containing salt forms. J Pharm Sci 2012;101(1):1–6 link1

[63] Thackaberry EA. Non-clinical toxicological considerations for pharmaceutical salt selection. Expert Opin Drug Metab Toxicol 2012;8(11):1419–33 link1

[64] Bolla G, Nangia A. Pharmaceutical cocrystals: Walking the talk. Chem Commun 2016;52(54):8342–60 link1

[65] Remenar JF, Morissette SL, Peterson ML, Moulton B, MacPhee JM, Guzmán HR, et al.Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids. J Am Chem Soc 2003;125(28):8456–7 link1

[66] Wang JR, Yu Q, Dai W, Mei X. Drug-drug co-crystallization presents a new opportunity for the development of stable vitamins. Chem Commun 2016;52(17):3572–5 link1

[67] Aitipamula S, Banerjee R, Bansal AK, Biradha K, Cheney ML, Choudhury AR, et al.Polymorphs, salts, and cocrystals: What’s in a name? Cryst Growth Des 2012;12(5):2147–52 link1

[68] US Food and Drug Administration. Guidance for industry: Regulatory classification of pharmaceutical co-crystals. Silver Spring: Center for Drug Evaluation and Research, US Food and Drug Administration; 2013 Apr.

[69] Chen Y, Li L, Yao J, Ma YY, Chen JM, Lu TB. Improving the solubility and bioavailability of apixaban via apixaban-oxalic acid cocrystal. Cryst Growth Des 2016;16(5):2923–30 link1

[70] Chattoraj S, Shi L, Chen M, Alhalaweh A, Velaga S, Sun CC. Origin of deteriorated crystal plasticity and compaction properties of a 1:1 cocrystal between piroxicam and saccharin. Cryst Growth Des 2014;14(8):3864–74 link1

[71] Weyna DR, Cheney ML, Shan N, Hanna M, Zaworotko MJ, Sava V, et al.Improving solubility and pharmacokinetics of meloxicam via multiple-component crystal formation. Mol Pharm 2012;9(7):2094–102 link1

[72] Aakeröy CB, Forbes S, Desper J. Using cocrystals to systematically modulate aqueous solubility and melting behavior of an anticancer drug. J Am Chem Soc 2009;131(47):17048–9 link1

[73] Steed JW. The role of co-crystals in pharmaceutical design. Trends Pharmacol Sci 2013;34(3):185–93 link1

[74] Duggirala NK, Perry ML, Almarsson Ö, Zaworotko MJ. Pharmaceutical cocrystals: Along the path to improved medicines. Chem Commun 2016;52(4):640–55 link1

[75] Wu TK, Lin SY, Lin HL, Huang YT. Simultaneous DSC-FTIR microspectroscopy used to screen and detect the co-crystal formation in real time. Bioorg Med Chem Lett 2011;21(10):3148–51 link1

[76] Thipparaboina R, Kumar D, Chavan RB, Shastri NR. Multidrug co-crystals: Towards the development of effective therapeutic hybrids. Drug Discov Today 2016;21(3):481–90 link1

[77] Fábián L. Cambridge structural database analysis of molecular complementarity in cocrystals. Cryst Growth Des 2009;9(3):1436–43 link1

[78] Hilfiker R, editor. Polymorphism: In the pharmaceutical industry. Hoboken: John Wiley & Sons, Inc.; 2006.

[79] Berziņš A, Skarbulis E, Rekis T, Actiņš A. On the formation of droperidol solvates: Characterization of structure and properties. Cryst Growth Des 2014;14(5):2654–64 link1

[80] Ulrich J, Frohberg P. Problems, potentials and future of industrial crystallization. Front Chem Sci Eng 2013;7(1):1–8 link1

[81] Ismail SZ, Anderton CL, Copley RC, Price LS, Price SL. Evaluating a crystal energy landscape in the context of industrial polymorph screening. Cryst Growth Des 2013;13(6):2396–406 link1

[82] Reilly AM, Cooper RI, Adjiman CS, Bhattacharya S, Boese AD, Brandenburg JG, et al.Report on the sixth blind test of organic crystal structure prediction methods. Acta Crystallogr B Struct Sci Cryst Eng Mater 2016;72(Pt 4 ):439–59 link1

[83] Price SL, Braun DE, Reutzel-Edens SM. Can computed crystal energy landscapes help understand pharmaceutical solids? Chem Commun 2016;52(44):7065–77 link1

[84] Myerson AS, Trout BL. Chemistry. Nucleation from solution. Science 2013;341(6148):855–6 link1

[85] Dandekar P, Kuvadia ZB, Doherty MF. Engineering crystal morphology. Annu Rev Mater Res 2013;43:359–86 link1

[86] Shtukenberg AG, Lee SS, Kahr B, Ward MD. Manipulating crystallization with molecular additives. Annu Rev Chem Biomol Eng 2014;5:77–96 link1

[87] Diao Y, Harada T, Myerson AS, Hatton TA, Trout BL. The role of nanopore shape in surface-induced crystallization. Nat Mater 2011;10(11):867–71 link1

[88] Diao Y, Myerson AS, Hatton TA, Trout BL. Surface design for controlled crystallization: The role of surface chemistry and nanoscale pores in heterogeneous nucleation. Langmuir 2011;27(9):5324–34 link1

[89] Diao Y, Whaley KE, Helgeson ME, Woldeyes MA, Doyle PS, Myerson AS, et al.Gel-induced selective crystallization of polymorphs. J Am Chem Soc 2012;134(1):673–84 link1

[90] Kacker R, Salvador PM, Sturm GS, Stefanidis GD, Lakerveld R, Nagy ZK, et al.Microwave assisted direct nucleation control for batch crystallization: Crystal size control with reduced batch time. Cryst Growth Des 2016;16(1):440–6 link1

[91] Ouyang JB, Wang JK, Huang X, Gao Y, Bao Y, Wang YL, et al.Gel formation and phase transformation during the crystallization of valnemulin hydrogen tartrate. Ind Eng Chem Res 2014;53(43):16859–63 link1

[92] Gao ZG, Li L, Bao Y, Wang Z, Hao HX, Yin QX, et al.From jellylike phase to crystal: Effects of solvent on self-assembly of cefotaxime sodium. Ind Eng Chem Res 2016;55(11):3075–83 link1

[93] Zhou G, Moment A, Cuff J, Schafer W, Orella C, Sirota E, et al.Process development and control with recent new FBRM, PVM, and IR. Org Process Res Dev 2015;19(1):227–35 link1

[94] Simone E, Saleemi AN, Nagy ZK. Raman, UV, NIR, and Mid-IR spectroscopy with focused beam reflectance measurement in monitoring polymorphic transformations. Chem Eng Technol 2014;37(8):1305–13 link1

[95] Simon LL, Pataki H, Marosi G, Meemken F, Hungerbühler K, Baiker A, et al.Assessment of recent process analytical technology (PAT) trends: A multiauthor review. Org Process Res Dev 2015;19(1):3–62 link1

[96] Simon LL, Merz T, Dubuis S, Lieb A, Hungerbuhler K. In-situ monitoring of pharmaceutical and specialty chemicals crystallization processes using endoscopy—Stroboscopy and multivariate image analysis. Chem Eng Res Des 2012;90(11):1847–55 link1

[97] El Arnaout T, Cullen PJ, Sullivan C. A novel backlight fiber optical probe and image algorithms for real time size-shape analysis during crystallization. Chem Eng Sci 2016;149:42–50 link1

[98] Pertig D, Buchfink R, Petersen S, Stelzer T, Ulrich J. Inline analyzing of industrial crystallization processes by an innovative ultrasonic probe technique. Chem Eng Technol 2011;34(4):639–46 link1

[99] Gherras N, Serris E, Févotte G. Monitoring industrial pharmaceutical crystallization processes using acoustic emission in pure and impure media. Int J Pharm 2012;439(1–2):109–19 link1

[100] Nagy ZK, Chew JW, Fujiwara M, Braatz RD. Comparative performance of concentration and temperature controlled batch crystallizations. J Process Contr 2008;18(3–4):399–407 link1

[101] Duffy D, Barrett M, Glennon B. Novel, calibration-free strategies for supersaturation control in antisolvent crystallization processes. Cryst Growth Des 2013;13(8):3321–32 link1

[102] Abu Bakar MR, Nagy ZK, Saleemi AN, Rielly CD. The impact of direct nucleation control on crystal size distribution in pharmaceutical crystallization processes. Cryst Growth Des 2009;9(3):1378–84 link1

[103] Nagy ZK, Fujiwara M, Braatz RD. Modelling and control of combined cooling and antisolvent crystallization processes. J Process Contr 2008;18(9):856–64 link1

[104] Mesbah A, Landlust J, Huesman AE, Kramer HJ, Jansens PJ, Van den Hof PM. A model-based control framework for industrial batch crystallization processes. Chem Eng Res Des 2010;88(9):1223–33 link1

[105] Aamir E, Rielly CD, Nagy ZK. Experimental evaluation of the targeted direct design of temperature trajectories for growth-dominated crystallization processes using an analytical crystal size distribution estimator. Ind Eng Chem Res 2012;51(51):16677–87 link1

[106] Nagy ZK. Model based robust control approach for batch crystallization product design. Comput Chem Eng 2009;33(10):1685–91 link1

[107] Trifkovic M, Sheikhzadeh M, Rohani S. Kinetics estimation and single and multi-objective optimization of a seeded, anti-solvent, isothermal batch crystallizer. Ind Eng Chem Res 2008;47(5):1586–95 link1

[108] Sheikhzadeh M, Trifkovic M, Rohani S. Real-time optimal control of an anti-solvent isothermal semi-batch crystallization process. Chem Eng Sci 2008;63(3):829–39 link1

[109] Moldoványi N, Lakatos BG, Szeifert F. Model predictive control of MSMPR crystallizers. J Cryst Growth 2005;275(1–2):e1349–54 link1

[110] Chianese A, Kramer HJ, editors. Industrial crystallization process monitoring and control. Hoboken: John Wiley & Sons, Inc.; 2012

[111] Lu J, Li YP, Wang J, Ren GB, Rohani S, Ching CB. Crystallization of an active pharmaceutical ingredient that oils out. Separ Purif Tech 2012;96:1–6 link1

[112] De Albuquerque I, Mazzotti M. Crystallization process design using thermodynamics to avoid oiling out in a mixture of vanillin and water. Cryst Growth Des 2014;14(11):5617–25 link1

[113] Takasuga M, Ooshima H. Control of crystal aspect ratio and size by changing solvent composition in oiling out crystallization of an active pharmaceutical ingredient. Cryst Growth Des 2015;15(12):5834–8 link1

[114] Yin YH, Gao ZG, Bao Y, Hou BH, Hao HX, Liu D, et al.Gelation phenomenon during antisolvent crystallization of cefotaxime sodium. Ind Eng Chem Res 2013;53(3):1286–92 link1

[115] Yang JX, Wang YL, Hao HX, Xie C, Bao Y, Yin QX, et al.Spherulitic crystallization of L-tryptophan: Characterization, growth kinetics, and mechanism. Cryst Growth Des 2015;15(10):5124–32 link1

[116] Paroli F. Industrial crystallizers design and control. In: Chianese A, Kramer HJ, editors Industrial crystallization process monitoring and control. Weinheim: Wiley-VCH; 2012. p. 203–24 link1

[117] Sultana M, Jensen KF, inventors; Massachusetts Institute of Technology, assignee. Systems and methods for microfluidic crystallization. United States patent US 20100298602 A1. 2010 Nov 25.

[118] Teychené S, Biscans B. Crystal nucleation in a droplet based microfluidic crystallizer. Chem Eng Sci 2012;77:242–8 link1

[119] Ildefonso M, Candoni N, Veesler S. A cheap, easy microfluidic crystallization device ensuring universal solvent compatibility. Org Process Res Dev 2012;16(4):556–60 link1

[120] Ildefonso M, Revalor E, Punniam P, Salmon JB, Candoni N, Veesler S. Nucleation and polymorphism explored via an easy-to-use microfluidic tool. J Cryst Growth 2012;342(1):9–12 link1

[121] Liu WJ, Ma CY, Liu JJ, Zhang Y, Wang XZ. Analytical technology aided optimization and scale-up of impinging jet mixer for reactive crystallization process. AIChE J 2015;61(2):503–17 link1

[122] Woo XY, Tan RB, Braatz RD. Modeling and computational fluid dynamics–population balance equation–micromixing simulation of impinging jet crystallizers. Cryst Growth Des 2009;9(1):156–64 link1

[123] Liu WJ, Ma CY, Liu JJ, Zhang Y, Wang XZ. Continuous reactive crystallization of pharmaceuticals using impinging jet mixers. AIChE J 2017;63(3):967−74 link1

[124] Kaur Bhangu S, Ashokkumar M, Lee J. Ultrasound assisted crystallization of paracetamol: Crystal size distribution and polymorph control. Cryst Growth Des 2016;16(4):1934–41 link1

[125] Soare A, Lakerveld R, van Royen J, Zocchi G, Stankiewicz AI, Kramer HJ. Minimization of attrition and breakage in an airlift crystallizer. Ind Eng Chem Res 2012;51(33):10895–909 link1

[126] Leonelli C, Mason TJ. Microwave and ultrasonic processing: Now a realistic option for industry. Chem Eng Process: Process Intensification. 2010;49(9):885–900 link1

[127] Soare A, Lakerveld R, van Royen J, Zocchi G, Stankiewicz AI, Kramer HJ. Minimization of attrition and breakage in an airlift crystallizer. Ind Eng Chem Res 2012;51(33):10895–909 link1

[128] Eder RJ, Radl S, Schmitt E, Innerhofer S, Maier M, Gruber-Woelfler H, et al.Continuously seeded, continuously operated tubular crystallizer for the production of active pharmaceutical ingredients. Cryst Growth Des 2010;10(5):2247–57 link1

[129] Lawton S, Steele G, Shering P. Continuous crystallization of pharmaceuticals using a continuous oscillatory baffled crystallizer. Org Process Res Dev 2009;13(6):1357–63 link1